1. Indications:

Caboxib (Cabozantinib) 80 mg is indicated for the treatment of:

• Advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy.
• Hepatocellular carcinoma (HCC) in patients who have previously received sorafenib.
• Metastatic medullary thyroid cancer (MTC) in patients with progressive disease.

2. Pharmacology:

Caboxib (Cabozantinib) 80 mg exerts its pharmacological effects by inhibiting the activity of multiple receptor tyrosine kinases (RTKs) involved in tumor growth, angiogenesis, and metastasis. It targets receptors such as MET, VEGFR, RET, AXL, and others, thereby disrupting signaling pathways crucial for cancer cell survival and progression.

3. Dosage and Administration:

The recommended dosage of Caboxib (Cabozantinib) 80 mg may vary depending on the type of cancer being treated and individual patient characteristics. Typically, the prescribed dose is 60 mg to 80 mg taken orally once daily, with or without food. Dosage adjustments or interruptions may be necessary based on the patient’s tolerance and treatment response.

4. Interaction:

Caboxib (Cabozantinib) 80 mg may interact with other medications, including:

• Strong CYP3A4 inhibitors or inducers: Co-administration with drugs that affect CYP3A4 metabolism may alter the plasma concentration of Caboxib.
• Anticoagulants: Concurrent use may increase the risk of bleeding complications.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to minimize the risk of potential interactions.

5. Side Effects:

Common side effects associated with Caboxib (Cabozantinib) 80 mg may include:

• Fatigue
• Diarrhea
• Hypertension
• Decreased appetite
• Palmar-plantar erythrodysesthesia (hand-foot syndrome)
• Nausea

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Caboxib (Cabozantinib) 80 mg, patients should be aware of the following precautions:

• Caboxib may cause hypertension, perforations or fistulas, and thrombotic events. Blood pressure should be monitored regularly, and patients should be monitored for signs of gastrointestinal perforation or thromboembolic events.
• Patients with a history of bleeding disorders or recent surgery should use caution when taking Caboxib, as it may increase the risk of bleeding.
• Caboxib may cause reversible posterior leukoencephalopathy syndrome (RPLS), a rare but serious neurological condition. Patients should seek medical attention if they experience symptoms such as headache, seizures, or visual disturbances.

7. Overdose Effects:

In case of overdose with Caboxib (Cabozantinib) 80 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Caboxib overdose, and patients should seek immediate medical attention if overdose is suspected.